- Funds will also support the R&D program for potentially availing Active Pharmaceutical Ingredients (APIs) to the pharmaceutical industry with compositions based on its botanical synthesis technology
- 2 years 9% interest notes with conversion at a share price of no less than CAD $0.32
Vancouver, British Columbia, and Rehovot, Israel--(Newsfile Corp. - February 21, 2023) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company") announced today a private placement of up to CAD $8 Million of two year convertible notes (the "Notes). The funds raised will predominantly support the Company's growth in its polyphenols/antioxidants vertical. The funds will also support the R&D program for potentially providing API's to the pharmaceutical industry on the basis of its botanical compositions.
BHSC has recently provided guidance for 2023 expected revenue to be in the range of USD 17M - 20M and cash flow breakeven target for Q4/2023. In addition, on February 9th the company announced its focus on: a) the growth of its core polyphenols business growth, b) the development of Pharmaceutical grade Cannabis compositions and c) the expansion of its clinical studies (see February 14th announcement) to support both the Nutraceuticals and Pharmaceutical verticals. This revised focus is expected to enable the Company to require less funds to achieve its 2023 financial targets and will likely result in less shareholder's dilution.
The Notes will be denominated in Canadian Dollars, will have a term of 24 months, and pay interest of 9% per annum. The Notes will be convertible as to principal and accrued interest , at the option of the holder, at any time from their issuance into common shares of the company at a price equal to the closing market price of the Company's common shares on the date of conversion (the ("Closing Price" ) less a discount of 20% but in any event not less than $0.32 per share (the "Floor Price") and not higher than a ceiling price (the "Ceiling Price") equal to $0.75 if converted within the term of the Notes. As an incentive for early conversion, any participating investor who converts their investment within the first year of the term of the Notes will receive a warrant for each $.40 converted (the Early Conversion Warrant) . Each Early Conversion Warrant will be exercisable to purchase a common share of the Company at a price of $.40 per share for a period expiring one year from the closing of the private placement of the Notes.
Investors who invest a minimum amount of $2,700,000 (the "Major Investment Threshold") will also receive an additional warrant (the Major Investment Warrant") for each $.40 invested. Each Major Investment Warrant will be exercisable for a period of one year from closing of the private placement of the Notes to purchase a common share of the Company at $.40 per share.
The Company may pay customary commissions or other sales incentives to registered brokers or investment dealers or finders (where permitted by law).
Ilan Sobel, CEO, states "The renewed focus on our core business is a blessing for our shareholders partners. Not only is it consistent with our biotech health and wellness vision, it enables us to responsibly execute on our goals with a less dilutive approach. Our strategy and priorities are sound. We are better positioned to deliver on what would make BioHarvest achieve the enterprise value worthy of a leading biotech innovator."
This news release is provided for information purposes only and it is not an offer for sale or solicitation of an offer to purchase securities of the Company in any United States jurisdiction or any other jurisdiction where prohibited by law. The company's proposed private placement will only be available to qualified investors.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.
BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer
For further information, please contact: Dave Ryan, VP Investor Relations & Director Phone: 1 (604) 622-1186
Facebook Twitter LinkedIn YouTube
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance the Company will achieve 2023 revenue of USD 17 to 20 Million or Q4 cash flow breakeven as these are subject to consumer acceptance and cost stability none of which can be assured. There is no assurance the company will achieve enterprise value of a leading biotech innovator as this depends on investor and market acceptance which cannot be assured.
All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/155643